10-Q quarterly report · filed Nov 4, 2026

Amgen (AMGN) Q3 2026 10-Q Quarterly Report

Short answer

Amgen (AMGN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10.4B (up 8.5% year over year) with net income of $3.9B.

Q3 2026 key financials · XBRL

Revenue
$10.4B
+8.5% YoY · +3.1% QoQ
Net income
$3.9B
+20.1% YoY · +62.7% QoQ
Operating margin
35.8%
EPS (diluted)
$7.08
+19.4% YoY · +62.0% QoQ

Source: XBRL data from the Amgen (AMGN) Q3 2026 10-Q on SEC EDGAR. USD.

Amgen Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $10,365M, up 8% YoY from $9,557M, driven by product-sales volume growth
  • Operating margin 35.8% vs 26.4% YoY, with operating income $3,710M vs $2,526M
  • Best product: Repatha $1,085M, worst: Prolia $1,139M, down 45% YoY amid biosimilar competition
  • Cash $13,190M vs $9,129M at December 31, 2025, with nine-month operating cash flow $10,432M vs $8,355M
  • Outlook: volume growth offset by net-price declines, with continued Prolia and XGEVA erosion from biosimilars

Risk Factors

  • TAVNEOS withdrawal risk: FDA proposed revoking U.S. approval after liver-injury concerns and questioned ADVOCATE data reliability
  • TAVNEOS international risk: European Commission revoked authorization in August 2026, with other regulators restricting or reviewing use
  • Medicare pricing pressure: CMS pricing reduced ENBREL profitability from January 1, 2026, with Otezla pricing beginning January 2027
  • State reimbursement risk: Colorado established an ENBREL upper payment limit effective no earlier than January 1, 2027
  • Regulatory capacity risk: FDA staffing and budget reductions could delay application reviews and approvals

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Amgen quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.